Abivax SA Sponsored ADR (NASDAQ:ABVX) Given Consensus Rating of “Moderate Buy” by Brokerages

Abivax SA Sponsored ADR (NASDAQ:ABVX) has been assigned an average rating of “Moderate Buy” from the thirteen research firms that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $128.7273.

Several research analysts have recently commented on the company. Wolfe Research upgraded Abivax to a “strong-buy” rating in a research report on Thursday, November 6th. Barclays began coverage on Abivax in a research note on Monday, October 13th. They set an “overweight” rating and a $142.00 price objective on the stock. BTIG Research boosted their target price on shares of Abivax from $112.00 to $120.00 and gave the company a “buy” rating in a research note on Monday, October 6th. Truist Financial set a $140.00 target price on shares of Abivax in a report on Monday, November 24th. Finally, Citigroup reaffirmed an “outperform” rating on shares of Abivax in a report on Tuesday.

Abivax Stock Performance

Shares of Abivax stock opened at $114.94 on Friday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 0.77 and a current ratio of 7.86. Abivax has a 1 year low of $4.77 and a 1 year high of $138.49. The firm’s 50-day simple moving average is $108.73 and its 200-day simple moving average is $71.42. The firm has a market cap of $8.96 billion, a PE ratio of -66.44 and a beta of 0.48.

Abivax (NASDAQ:ABVX) last announced its quarterly earnings data on Monday, December 15th. The company reported ($2.46) earnings per share for the quarter. The company had revenue of ($4.92) million during the quarter. Equities analysts forecast that Abivax will post -2.83 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Abivax

A number of hedge funds and other institutional investors have recently bought and sold shares of ABVX. Kennedy Capital Management LLC raised its stake in shares of Abivax by 7.1% in the 2nd quarter. Kennedy Capital Management LLC now owns 241,188 shares of the company’s stock worth $1,845,000 after buying an additional 15,997 shares in the last quarter. Quadrature Capital Ltd purchased a new stake in shares of Abivax in the 2nd quarter valued at approximately $148,000. Saturn V Capital Management LP lifted its position in shares of Abivax by 12.6% in the 2nd quarter. Saturn V Capital Management LP now owns 622,479 shares of the company’s stock valued at $4,762,000 after acquiring an additional 69,553 shares in the last quarter. Octagon Capital Advisors LP acquired a new position in Abivax in the 1st quarter worth approximately $7,688,000. Finally, Affinity Asset Advisors LLC purchased a new position in Abivax during the 1st quarter worth approximately $1,250,000. 47.91% of the stock is currently owned by institutional investors and hedge funds.

About Abivax

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.